Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.

Date publication

juillet 2017

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, Phelip JM, Peyrin-Biroulet L, Colombel JF, Del Tedesco E, Paul S, Flourie B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28449228

Résumé

Infliximab (IFX) combined with azathioprine (AZA) is more effective than IFX monotherapy in inflammatory bowel disease (IBD).

Mots clés

Adult, Aged, Antirheumatic Agents, administration & dosage, Azathioprine, administration & dosage, Clinical Protocols, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Inflammatory Bowel Diseases, drug therapy, Infliximab, administration & dosage, Male, Middle Aged, Prospective Studies, Young Adult

Référence

Aliment. Pharmacol. Ther.. 2017 07;46(2):142-149